サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1606515

AI活用型医用画像ソリューションの世界市場-2024～2031年

Global AI-Enabled Medical Imaging Solutions Market - 2024-2031

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
AI活用型医用画像ソリューションの世界市場-2024～2031年
出版日: 2024年12月04日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

AI活用型医療用画像ソリューションの世界市場は、2023年に11億2,000万米ドルに達し、2031年には126億4,000万米ドルに達すると予測され、予測期間2024～2031年のCAGRは35.6%で成長する見込みです。

AI活用型医療用画像ソリューションは、診断画像の撮影、分析、解釈、報告のプロセスを強化するために、人工知能（AI）技術を医療画像セグメントに統合することを指します。これらのソリューションは、機械学習（ML）、深層学習（DL）、自然言語処理（NLP）、コンピュータビジョンなどの先進的AIアルゴリズムを活用し、画像強調、セグメンテーション、解釈、意思決定支援など、医療画像ワークフローのさまざまな側面を自動化・改善します。

AI活用型医療用画像ソリューションの市場需要は、技術の進歩、医療ニーズの増加、放射線医療における人工知能への嗜好の高まりにより急速に拡大しています。例えば、北米放射線学会によると、現在の医療市場では、放射線科医向けのAIツールが主流となっています。FDAが認可した500以上のAIアルゴリズムのうち75％が放射線科診療を対象としており、70％から増加しています。

市場力学：

促進要因と抑制要因

高齢化人口の増加

高齢化率の上昇がAI活用型医療用画像ソリューション市場の成長を大きく牽引しており、予測期間中も市場を牽引すると予測されます。世界人口の高齢化に伴い、がん、心血管疾患、神経変性疾患、筋骨格系障害などの加齢関連疾患の有病率が上昇します。これらの疾患には、頻繁なモニタリング、早期発見、正確な診断が必要であり、AI対応画像ソリューションによってより効率的に達成することができます。

AIアルゴリズムは、放射線科医による医療画像の分析をより正確かつ迅速に支援し、人為的ミスを減らして迅速な診断を可能にします。高齢の患者は一度に複数の健康状態を評価する必要があることが多いため、複雑な医療画像の優先順位付け、分析、解釈を行うAIの能力は、患者の転帰を改善する上で極めて重要です。

例えば、世界保健機関（WHO）によると、2030年までに世界の6人に1人が60歳以上の高齢者となります。この時、60歳以上の人口に占める割合は2020年の10億人から14億人に増加します。2050年には、世界の60歳以上人口は2倍（21億人）になります。80歳以上の高齢者の数は2020～2050年の間に3倍になり、4億2,600万人に達すると予想されています。

さらに、NCOAの調査によると、60歳以上の成人の95％近くが少なくとも1つの慢性疾患を抱えており、80％近くが2つ以上の慢性疾患を抱えています。また、WHOによると、がんの罹患率は人生の後半になると劇的に上昇します。実際、2022年には、がんにかかった人の約53％が65歳以上でした。AIを活用した画像診断は、乳がん、肺がん、前立腺がんなど、高齢者に多いがんの早期発見に有効であることが証明されています。

データのプライバシーとセキュリティへの懸念

データのプライバシーとセキュリティに関する懸念は、AI活用型医療用画像ソリューション市場の成長を妨げる重大な課題です。こうした懸念は主に、医療データの機密性、AIシステムの複雑性、医療組織を標的としたサイバー攻撃の増加によって生じています。

MRIスキャン、CTスキャン、X線などの医療画像データには、非常に機微な個人健康情報が含まれています。このデータは、クラウドベースのシステムに保存されたり、AI分析のためにネットワーク経由で送信されたりすることが多く、不正アクセスに対して脆弱です。機密性の高い患者データが漏洩した場合、個人のプライバシーが危険にさらされるだけでなく、医療プロバイダーやAIベンダーの評判も損なわれ、患者の信頼を失い、AI技術の導入が減少する可能性があります。

例えば、コロラド州を拠点とする病理学研究所は、米国連邦規制当局に医療検査研究所から報告された最大規模の情報漏洩の1つである、180万人以上の患者の機密情報が漏洩したことを通知しており、医療産業はハッカーに対して特に脆弱になっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 高齢化人口の増加
      • 迅速な分析と意思決定
    • 抑制要因
      • データのプライバシーとセキュリティに関する懸念
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 特許分析
  • 規制分析
  • SWOT分析
  • アンメットニーズ

第6章 画像診断法別

  • X線画像
  • 磁気共鳴画像（MRI）
  • コンピュータ断層撮影（CT）
  • 超音波画像診断
  • マンモグラフィー
  • その他

第7章 展開モード別

  • クラウドベースのソリューション
  • オンプレミスソリューション
  • ハイブリッドモデル

第8章 用途別

  • 腫瘍学
  • 心臓病学
  • 神経学
  • 呼吸器疾患
  • 整形外科
  • 消化器内科
  • その他

第9章 エンドユーザー別

  • 病院
  • 診断センター
  • 専門クリニック
  • 学術研究機関

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他の欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • deepc GmbH
  • Qure.ai Technologies Private Limited
  • DeepTek.ai, Inc
  • Aidoc
  • Tempus AI, Inc.
  • Rayscape
  • Infervision
  • AIKENIST
  • Rad AI
  • Brainomix Limited

第13章 付録

目次
Product Code: MI8813

Overview

The global AI-enabled medical imaging solutions market reached US$ 1.12 billion in 2023 and is expected to reach US$ 12.64 billion by 2031, growing at a CAGR of 35.6% during the forecast period 2024-2031.

AI-enabled medical imaging solutions refer to the integration of artificial intelligence (AI) technologies into the field of medical imaging to enhance the process of capturing, analyzing, interpreting and reporting diagnostic images. These solutions utilize advanced AI algorithms, including machine learning (ML), deep learning (DL), natural language processing (NLP) and computer vision to automate and improve various aspects of medical imaging workflows, such as image enhancement, segmentation, interpretation and decision support.

The market demand for AI-enabled medical imaging solutions is growing rapidly due to technological advancements, increasing healthcare needs and a growing preference for Artificial Intelligence in radiology. For instance, according to the Radiological Society of North America, in the current healthcare market, AI tools for radiologists dominate. Seventy-five percent of the over 500 FDA-cleared AI algorithms target radiology practice, increasing from 70%.

Market Dynamics: Drivers & Restraints

Rising aging population

The rising aging population is significantly driving the growth of the AI-enabled medical imaging solutions market and is expected to drive the market over the forecast period. As the global population ages, the prevalence of age-related diseases like cancer, cardiovascular conditions, neurodegenerative diseases and musculoskeletal disorders rises. These conditions require frequent monitoring, early detection and accurate diagnosis, which can be achieved more efficiently with AI-enabled imaging solutions.

AI algorithms can assist radiologists in analyzing medical images more accurately and swiftly, reducing human error and providing quicker diagnosis. Given that elderly patients often have multiple health conditions that need to be evaluated at once, AI's ability to prioritize, analyze, and interpret complex medical images is crucial for improving patient outcomes.

For instance, according to the World Health Organization, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Additionally, According to NCOA research, nearly 95% of adults 60 and older have at least one chronic condition, while nearly 80% have two or more. And, according to the WHO, the incidence of cancer rises dramatically at a later stage in life. In fact, in 2022 about 53% of people who had cancer were 65 or older. AI-powered imaging has proven to be effective in early detection of cancers like breast cancer, lung cancer and prostate cancer conditions that are more prevalent in older adults.

Data privacy and security concerns

Data privacy and security concerns are significant challenges that are hampering the growth of the AI-enabled medical imaging solutions market. These concerns primarily arise due to the sensitive nature of medical data, the complexity of AI systems and the increasing incidents of cyberattacks targeting healthcare organizations.

Medical imaging data, such as MRI scans, CT scans and X-rays, contains highly sensitive personal health information. This data is often stored in cloud-based systems or transmitted over networks for AI analysis, making it vulnerable to unauthorized access. If sensitive patient data is compromised, it not only jeopardizes individual privacy but also damages the reputation of healthcare providers and AI vendors, potentially leading to loss of patient trust and reduced adoption of AI technologies.

For instance, a Colorado-based pathology laboratory is notifying more than 1.8 million patients that their sensitive information was compromised one of the largest breaches reported by a medical testing lab to US federal regulators, making the healthcare industry especially vulnerable to hackers.

Segment Analysis

The global AI-enabled medical imaging solutions market is segmented based on imaging modality, deployment mode, application, end-user and region.

Application:

The oncology segment is expected to dominate the global AI-enabled medical imaging solutions market share

The oncology segment holds a major portion of the AI-enabled medical imaging solutions market share and is expected to continue to hold a significant portion of the market share over the forecast period. his dominance is primarily driven by the critical need for early cancer detection, improved diagnostic accuracy and the growing adoption of AI technologies in oncology diagnostics.

Cancer is one of the leading causes of death worldwide. According to the World Health Organization (WHO), nearly 10 million people die from cancer each year. As cancer rates increase globally, the demand for effective diagnostic tools, including AI-powered medical imaging solutions, rises.

Early detection is crucial in improving cancer survival rates. AI has shown its potential to enhance the accuracy and speed of detecting cancers at an early stage. AI-enabled imaging solutions can analyze medical images (such as CT scans, MRIs, and mammograms) for early signs of cancer, enabling more effective and timely treatment.

For instance, the Harvard University team tested the AI tool, CHIEF (Clinical Histopathology Imaging Evaluation Foundation) performance on more than 19,400 whole-slide images from 32 independent datasets collected from 24 hospitals and patient cohorts across the globe. CHIEF achieved nearly 94 percent accuracy in cancer detection and significantly outperformed current AI approaches across 15 datasets containing 11 cancer types.

North America is expected to hold a significant position in the global AI-enabled medical imaging solutions market

North America region is expected to hold the largest market share over the forecast period. North America, particularly the United States and Canada, has some of the most advanced healthcare systems globally. These systems have the infrastructure and resources needed to implement and scale AI-driven medical imaging solutions.

For instance, the U.S. healthcare market is one of the largest in the world, with healthcare spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person, according to the Centers for Medicare & Medicaid Services (CMS). This substantial investment supports the adoption of cutting-edge technologies like AI in medical imaging to improve diagnostic accuracy and efficiency.

North America especially in the United States, is a global leader in artificial intelligence innovation, with tech giants heavily involved in the development of AI technologies for healthcare applications, including medical imaging. For instance, in April 2023, Exo cleared its FDA-cleared cardiac and lung artificial intelligence (AI) applications are available on Exo Iris, Exo's high-performance handheld ultrasound device. With affordable, AI-powered medical imaging in a pocket-sized device, caregivers can get answers immediately to accelerate diagnosis and create new care pathways for heart failure patients at the point of care.

Asia Pacific is growing at the fastest pace in the AI-enabled medical imaging solutions market

The Asia Pacific region is experiencing the fastest growth in the AI-enabled medical imaging solutions market. The Asia Pacific region is home to 60% of the world's population, with over 4.3 billion people. This large and diverse population presents a significant demand for healthcare services, including advanced diagnostic solutions like AI-powered medical imaging. As the population grows, so does the prevalence of health conditions such as cancer, cardiovascular diseases and neurological disorders, driving the demand for AI-powered diagnostic tools to help healthcare providers manage these conditions more effectively.

For instance, China and India, with populations over 1.4 billion and 1.4 billion respectively, are seeing a rise in diseases like lung cancer and diabetes, which are major drivers for the adoption of AI medical imaging tools in early detection and diagnosis.

Asia-Pacific countries are seeing a significant rise in chronic diseases, such as cancer, cardiovascular diseases and diabetes, necessitating the adoption of advanced diagnostic tools like AI-driven imaging to detect these diseases in their early stages. For instance, India has seen a rising incidence of cancer, with the Indian Council of Medical Research (ICMR) estimating that cancer cases will increase by more than 25% by 2035, highlighting the demand for AI-enabled imaging solutions for early diagnosis.

Competitive Landscape

The major global players in the AI-enabled medical imaging solutions market include deepc GmbH, Qure.ai Technologies Private Limited, DeepTek.ai, Inc, Aidoc, Tempus AI, Inc., Rayscape, Infervision, AIKENIST, Rad AI, Brainomix Limited and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global artificial organs and bionics market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Imaging Modality
  • 3.2. Snippet by Deployment Mode
  • 3.3. Snippet by Application
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Aging Population
      • 4.1.1.2. Rapid Analysis and Decision Making
    • 4.1.2. Restraints
      • 4.1.2.1. Data Privacy and Security Concerns
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Imaging Modality

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 6.1.2. Market Attractiveness Index, By Imaging Modality
  • 6.2. X-ray Imaging*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Magnetic Resonance Imaging (MRI)
  • 6.4. Computed Tomography (CT)
  • 6.5. Ultrasound Imaging
  • 6.6. Mammography
  • 6.7. Others

7. By Deployment Mode

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
    • 7.1.2. Market Attractiveness Index, By Deployment Mode
  • 7.2. Cloud-Based Solutions*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. On-Premise Solutions
  • 7.4. Hybrid Models

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Oncology*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Cardiology
  • 8.4. Neurology
  • 8.5. Respiratory Disorders
  • 8.6. Orthopedics
  • 8.7. Gastroenterology
  • 8.8. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Centers
  • 9.4. Specialty Clinics
  • 9.5. Academic and Research Institutes

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. deepc GmbH*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Qure.ai Technologies Private Limited
  • 12.3. DeepTek.ai, Inc
  • 12.4. Aidoc
  • 12.5. Tempus AI, Inc.
  • 12.6. Rayscape
  • 12.7. Infervision
  • 12.8. AIKENIST
  • 12.9. Rad AI
  • 12.10. Brainomix Limited

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us